2020 Pediatric Rheumatology Symposium

April 29-May 2, 2020

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

View by Number View by Title View Sessions

View by Date

Saturday, May 2, 2020

4:15PM-5:15PM: Abstract Number: 139

Ongoing Disease Activity in Juvenile Idiopathic Arthritis (JIA) 18 Years After Disease Onset: A Population-based Nordic Study

Poster Session 3

4:15PM-5:15PM: Abstract Number: 190

Outcomes of an Evidence Based Guideline for the Treatment of Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome

Poster Session 3

4:15PM-5:15PM: Abstract Number: 116

Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry

Poster Session 3

4:15PM-5:15PM: Abstract Number: 133

Pediatric Rheumatology Consultation for Both Traditional and Emerging Rheumatic Diseases in the Critical Care Setting

Poster Session 3

4:15PM-5:15PM: Abstract Number: 187

Perspectives of Adolescents and Young Adults Around Implementing Rheumatology Healthcare Transition: Preliminary Qualitative Findings

Poster Session 3

4:15PM-5:15PM: Abstract Number: 185

pGALS Training Increases Canadian and Kenyan Physicians’ Confidence in Examining the Musculoskeletal System in Children

Poster Session 3

4:15PM-5:15PM: Abstract Number: 124

Pharmacist Role in an Outpatient Adolescent Complex Pediatric Lupus Clinic

Poster Session 3

4:15PM-5:15PM: Abstract Number: 131

Practice Patterns for Consulting Pediatric Rheumatology in a Large Pediatric Intensive Care Unit

Poster Session 3

4:15PM-5:15PM: Abstract Number: 128

Predictors of Moderate/High Disease Activity in Childhood-Onset Systemic Lupus Erythematosus

Poster Session 3

4:15PM-5:15PM: Abstract Number: 136

Prevalence of Paradoxical Psoriasis After Exposure to Tumor Necrosis Factor Inhibitors (TNFi) in Children from a Single Tertiary Center

Poster Session 3

4:15PM-5:15PM: Abstract Number: 129

Reproductive Health Concerns in Young Adults with Pediatric Onset Rheumatic Diseases

Poster Session 3

4:15PM-5:15PM: Abstract Number: 166

Resident Memory T Cells in Human RA Synovium Display Restricted TCR Clones

Poster Session 3

4:15PM-5:15PM: Abstract Number: 138

Serious Infection Risk in Pediatric Patients with Low Immunoglobulin Levels Following Rituximab Treatment for Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)

Poster Session 3

4:15PM-5:15PM: Abstract Number: 140

Serum Biomarkers in a German Cohort of Patients with Systemic Juvenile Idiopathic Arthritis and Their Relationship to Response to Interleukin-1 Blockade

Poster Session 3

4:15PM-5:15PM: Abstract Number: 192

Single Center Consensus of Prophylactic Treatment in Immunocompromised Children with Rheumatic Disease

Poster Session 3

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].